Evaluation of the effect of Infliximab (a biological drug) on lesions caused by calcium deposition in patients with juvenile dermatomyositis

Phase 2

Recruiting

• Conditions: Juvenile Dermatomyositis (JDM).; Juvenile dermatomyositis; M33.0

• Registration Number: IRCT20210808052107N1
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 29 August 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 5

Inclusion Criteria

Definitive diagnosis of juvenile dermatomyositis
Presence of calcinous lesions

Exclusion Criteria

Patients with Calcinosis lesion size greater than 5 cm2
Presence of calcinosis lesion in life threatening organs

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
umber of calcinosis lesions. Timepoint: At baseline and weekly for up to 10 weeks. Method of measurement: It will be determined weekly by a pediatric rheumatologist. The number of lesions will be recorded.;Size of calcinosis lesions. Timepoint: At baseline and weekly for up to 10 weeks. Method of measurement: It will be determined weekly by a pediatric rheumatologist. The size of the lesions will be recorded in square centimeters.;Consistency of calcinosis lesions. Timepoint: At baseline and weekly for up to 10 weeks. Method of measurement: It will be determined weekly by a pediatric rheumatologist. The consistency of the lesions will be recorded as the physician estimates whether the lesion is softer or not.